These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28992986)

  • 1. Pros and cons of vaccination against serogroup B meningococcal disease.
    Delgado Rodríguez M; Domínguez García Á
    Med Clin (Barc); 2018 Feb; 150(3):109-113. PubMed ID: 28992986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults.
    Leeds IL; Namasivayam V; Bamogo A; Sankhla P; Thayer WM
    Am J Prev Med; 2019 Feb; 56(2):196-204. PubMed ID: 30573332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.
    Gasparini R; Landa P; Amicizia D; Icardi G; Ricciardi W; de Waure C; Tanfani E; Bonanni P; Lucioni C; Testi A; Panatto D
    Hum Vaccin Immunother; 2016 Aug; 12(8):2148-2161. PubMed ID: 27163398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease.
    La EM; Talbird SE; Kanadanian KV; Huang L; Fain J; Srivastava A
    Hum Vaccin Immunother; 2019; 15(4):978-986. PubMed ID: 30526279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
    Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
    Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(®) to reduce meningococcal group B disease in Germany.
    Christensen H; Irving T; Koch J; Trotter CL; Ultsch B; Weidemann F; Wichmann O; Hellenbrand W
    Vaccine; 2016 Jun; 34(29):3412-9. PubMed ID: 27109566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vaccination against meningococcal B disease. Public statement of the Advisory Committee on Vaccines of the Spanish Association of Paediatrics (CAV-AEP)].
    Moreno-Pérez D; Álvarez García FJ; Arístegui Fernández J; Cilleruelo Ortega MJ; Corretger Rauet JM; García Sánchez N; Hernández Merino A; Hernández-Sampelayo Matos T; Merino Moína M; Ortigosa Del Castillo L; Ruiz-Contreras J;
    An Pediatr (Barc); 2015 Mar; 82(3):198.e1-9. PubMed ID: 25304451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Meningococcal C conjugate vaccine: Impact of a vaccination program and long-term effectiveness in Navarra, Spain, 2000-2014].
    Morales D; García-Cenoz M; Moreno L; Bernaola E; Barricarte A; Castilla J
    Enferm Infecc Microbiol Clin; 2016 Dec; 34(10):639-644. PubMed ID: 26778101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact.
    Christensen H; Hickman M; Edmunds WJ; Trotter CL
    Vaccine; 2013 May; 31(23):2638-46. PubMed ID: 23566946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The costs associated with the public health management of a cluster of meningococcal infection in England.
    Letouze D; Yao G; Clarke SC
    Vaccine; 2014 Sep; 32(43):5549-51. PubMed ID: 25173479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.
    Pouwels KB; Hak E; van der Ende A; Christensen H; van den Dobbelsteen GP; Postma MJ
    Hum Vaccin Immunother; 2013 May; 9(5):1129-38. PubMed ID: 23406816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.
    Izquierdo G; Torres JP; Santolaya ME; Valenzuela MT; Vega J; Chomali M
    Hum Vaccin Immunother; 2015; 11(4):875-83. PubMed ID: 25714390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meningococcal vaccines: Current state and future outlook.
    Leca M; Bornet C; Montana M; Curti C; Vanelle P
    Pathol Biol (Paris); 2015 Jun; 63(3):144-51. PubMed ID: 25986879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunisation against meningococcus B.
    Eskola J
    Lancet; 2013 Sep; 382(9897):1019. PubMed ID: 24054532
    [No Abstract]   [Full Text] [Related]  

  • 15. Advances with vaccination against Neisseria meningitidis.
    Borrow R
    Trop Med Int Health; 2012 Dec; 17(12):1478-91. PubMed ID: 22947250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reply to: Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact.
    Wassil J; Huels J; Narasimhan V
    Vaccine; 2014 May; 32(25):2943. PubMed ID: 23962533
    [No Abstract]   [Full Text] [Related]  

  • 17. Epidemiological impact and cost-effectiveness of universal meningitis b vaccination among college students prior to college entry.
    Chung GS; Hutton DW
    PLoS One; 2020; 15(10):e0239926. PubMed ID: 33035260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.
    de Moraes JC; Perkins BA; Camargo MC; Hidalgo NT; Barbosa HA; Sacchi CT; Landgraf IM; Gattas VL; Vasconcelos Hde G
    Lancet; 1992 Oct; 340(8827):1074-8. PubMed ID: 1357461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is public meningococcal C vaccination the preferred value for money at cost-neutral?
    Gravatt L
    N Z Med J; 2013 Oct; 126(1384):123-5. PubMed ID: 24162638
    [No Abstract]   [Full Text] [Related]  

  • 20. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.
    Esposito S; Principi N
    Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.